




The Centers for Disease Control and Prevention (CDC1) has issued the  
“Human Research Protections” Policy 
 
1. Reason for Issue: This policy is CDC’s first policy on Human Research Protections 
and it affirms CDC’s commitment to protecting the rights and welfare of all 
participants in research.  This policy will strengthen CDC’s position as a leader in 
ethical public health research.   
 
2. Summary of Policy: All of CDC’s human research activities will be guided by the 
ethical principles of respect for persons, beneficence, and justice. The policy 
specifically:  
 
• Defines and describes the human research protection program  
• Explains the supporting regulation requirements 
• Provides example of activities not covered by human research regulations 
• Delineates responsibilities of investigators, supervisors, and other stakeholders 
necessary to support the human research protection program 
 
3. Related Issues: CDC Policy, Distinguishing Public Health Research and Public 
Health Nonresearch 
 
4. Responsible Officials: Office of the Associate Director for Science  
 
5. Material Superseded: None 
 
6. Recertification: This document is scheduled for recertification on or before the last 
working day of July 2015. 
 
7. Point of Contact: Tom Jones, Policy Analyst, Management Analysis and Services 
Office 404-498-516.   
 
To go directly to the policy, click on the link below or enter the following URL into the 






Deputy Chief Operating Officer 
 
1 References to CDC also apply to the Agency for Toxic Substances and Disease Registry (ATSDR) 
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1. PURPOSE 
This policy affirms the Centers for Disease Control and Prevention’s (CDC) commitment 
to protecting the rights and welfare of all participants in research with which CDC is 
associated by enumerating specific roles, responsibilities, and procedures for CDC staff. 
Human research is defined and governed by HHS and other regulations: 
The Basic Policy for Protection of Human Research Subjects (the Common Rule), 
codified for HHS at Title 45, Part 46, Subpart A of the Code of Federal Regulations 
Additional HHS protections for specified vulnerable populations at Title 45, Part 46, 
Subparts B, C, and D of the Code of Federal Regulations 
Clinical investigations regulated by the Food and Drug Administration, particularly 
Title 21, Parts 50 and 56 of the Code of Federal Regulations 
All of CDC’s human research activities, whether subject to the above federal regulations 
or not, will be guided by the ethical principles of respect for persons, beneficence, and 
justice. Thus, this policy extends CDC’s commitment beyond CDC activities covered by 
these regulations, to cover additional activities sponsored or supported by CDC or in 
which CDC has substantial involvement. 
2. SCOPE 
This policy applies to the following persons, whether located in the United States or 
another country: 
• Employees or agents of CDC who intervene or interact with human research 
participants or obtain or use identifiable private information or specimens for research 
purposes; 
• CDC employees who conduct or oversee, or lead a team that conducts or oversees, a 
clinical investigation; 
• CDC employees who create, distribute, or disseminate information products or other 
resources (such as public-use datasets) outside CDC using information or specimens 
obtained during research or a clinical investigation; 
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• CDC employees who have the authority to allocate, commit, or release resources 
(including financial support, identifiable private information or specimens, or other 
tangible goods) for human research activities or clinical investigations by CDC 
programs or non-CDC entities; and 
• CDC employees who have scientific or administrative oversight of persons in items the 
previous 4 items. 
For guidance on interpreting the regulatory definition of human research, please see CDC 
Policy CDC-SA-2010-02, Distinguishing Public Health Research and Public Health 
Nonresearch. See the references section for additional Departmental and agency policies 
that apply to human research and clinical investigations. 
This policy is not intended to create any new requirements for external partners; its scope 
is limited to procedures within the agency and existing legal requirements for external 
partners. If there are any statements in this policy that are unintentionally inconsistent with 
other regulations or agreements, this policy is superseded by regulations promulgated by 
the Office for Human Research Protections (OHRP) and by the Food and Drug 
Administration (FDA), as well as the terms of the Federalwide Assurance of Compliance 
between CDC and OHRP. 
3. BACKGROUND 
CDC’s human research protection program (HRPP) is comprised of every component 
throughout the agency that participates in planning, reviewing, executing, or 
administratively supporting research involving human participants. Ethical responsibilities 
for human research protections extend, for example, to CDC investigators who directly 
interact with research participants, project officers who provide technical assistance, 
associate directors for science who provide an early line of critique to assure high-quality 
science and ethics, management officials who direct the allocation of agency resources, 
institutional review board (IRB) members who carry out the charge for autonomous 
review, contract specialists who authorize the disbursement of funds for human research, 
and laboratorians who analyze specimens that can be traced to unique individuals. CDC’s 
IRBs play a vital but limited role in this enterprise; all components of CDC’s human 
research protection program must remain accountable to the public trust. 
CDC participates in several activities that incur specific regulatory responsibilities related 
to human research protections: conducting nonexempt human research or clinical 
investigations, supporting nonexempt human research, sponsoring clinical investigations, 
and managing the functions of CDC IRBs. These roles can occur in any combination; the 
policy section expands on their regulatory implications. 
CDC’s ethical responsibilities extend beyond the ambit of these specific regulated 
activities, such as carrying out research activities that entail risks to privacy or 
confidentiality but that do not involve identifiable private information as defined at 45 CFR 
46.102(f); carrying out human research that is exempt from 45 CFR part 46; assisting or 
collaborating on human research or clinical investigations when CDC has no institutional 
responsibilities under human research regulations; setting priorities and allocating 
resources for research; and applying or disseminating knowledge derived from human 
research, such as coauthoring a manuscript or writing public health guidelines. 





All of CDC’s human research activities, regardless of whether the research is subject to 
federal regulations, will be guided by the ethical principles of respect for persons, 
beneficence, and justice as defined in The Belmont Report.  
CDC preserves the definitional distinction between HHS-defined human research and 
FDA-defined clinical investigations, because CDC conducts a nonnegligible number of 
clinical investigations that do not constitute human research as defined by HHS. Activities 
that meet the regulatory definitions of human research or clinical investigation may be 
exempt from some or all regulatory requirements, or CDC’s role may be such that CDC 
has no regulatory responsibilities (because, for example, CDC is neither conducting nor 
supporting the activity). 
A. Activities covered by human research regulations 
For each role that incurs specific regulatory responsibilities related to human research 
protections, CDC will identify and comply with all relevant regulations. 
• As an institution that conducts nonexempt human research1
o CDC must maintain a valid Federalwide Assurance (FWA); certify approval by a 
CDC or non-CDC IRB for each research activity; and, comply with 45 CFR part 46 (all 
subparts) and 21 CFR parts 50 and 56, as applicable 
 or clinical investigations 
(that is, whose employees or agents obtain research data from individuals through 
intervention or interaction with them; obtain identifiable, private information for research 
purposes; or directly oversee the administration of an investigational drug or device): 
o CDC may extend its FWA to cover human research activities of nonsupported 
collaborators 
• As a federal institution agency that supports nonexempt human research: 
CDC must confirm that each supported institution engaged in nonexempt human research 
holds a valid FWA and certifies IRB approval. 
• As an institution that sponsors clinical investigations: 
CDC must manage or supervise investigations in compliance with FDA requirements and 
assure, through investigators, that IRBs operate in compliance with 21 CFR part 56 and 
that investigators comply with FDA requirements. 
• As an IRB organization that manages IRB functions: 
o CDC IRBs (or other designated IRBs) must review nonexempt human research 
activities that are to be conducted by CDC under CDC’s FWA. CDC IRBs (or other 
designated IRBs) must also review clinical investigations conducted by CDC 
investigators 
o CDC may, with an appropriately documented agreement, review non-CDC-
conducted, nonexempt human research activities under the corresponding FWA. 
CDC may also, with an appropriately documented agreement, review clinical 
investigations conducted by non-CDC investigators 
Acting under the authority of the CDC institutional official for human research protections, 
the CDC Human Research Protection Office (HRPO) is responsible for leading the agency 
                                               
1 For CDC, “to conduct human research” is the same as “to be engaged in human research”. 
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in protecting the rights and welfare of those who participate in CDC-sponsored public 
health research, through the practices of investigators, program leaders, and the CDC 
IRBs, and through relationships with external partners. HRPO must be located within the 
managerial purview of the institutional official.  
All CDC-conducted activities that are covered by human research regulations will be 
reviewed, prospectively approved, and subject to continuing review at least annually by 
designated IRBs. The IRBs are authorized to approve, require modifications in, or 
disapprove the covered human research. For activities approved by the designated IRBs, 
further appropriate review and approval by CDC officials or other institutions may be 
required. CDC officials may not permit CDC investigators to conduct research that is 
disapproved, suspended, or terminated by the IRB of record, or for which IRB approval 
has lapsed. 
HRPO shall develop and maintain written procedures for ensuring prompt reporting to the 
IRB, appropriate institutional officials, the head of any department or agency conducting or 
supporting the research (or designee), and any applicable regulatory body of any:  
• Unanticipated problems involving risks to participants or others 
• Serious or continuing noncompliance with the federal regulations or the requirements 
or determinations of the IRB(s); and  
• Suspension or termination of IRB approval 
HRPO will ensure that the designated IRBs agree to comply with the terms of CDC’s FWA 
and other relevant regulations; possess appropriate knowledge of the local research 
context for all research to which the FWA applies; and have established written 
procedures for the following activities:  
• Conducting IRB initial and continuing review (not less than once per year) of research, 
and reporting IRB findings to the investigator and CDC;  
• Determining which projects require review more often than annually and which 
projects need verification from sources other than the investigator that no material 
changes have occurred since the previous IRB review; and  
• Ensuring prompt reporting to the IRB of proposed changes in a research activity and 
for ensuring that such changes in approved research, during the period for which IRB 
approval has already been given, may not be initiated without IRB review and 
approval, except when necessary to eliminate apparent immediate hazards to the 
participants. 
B. Activities not covered by human research regulations 
CDC’s ethical responsibilities extend beyond the ambit of specific regulated activities. The 
following related activities also require ethical judgment and action:  
• Carrying out research activities that entail risks to privacy or confidentiality but that do 
not involve identifiable private information as defined at 45 CFR 46.102(f): 
o CDC is required to apply other legal protections of privacy and confidentiality, as 
applicable, including the Privacy Act, the HIPAA Privacy Rule, provisions of 
certificates and assurances of confidentiality under sections 301(d) and 308(d) of 
the Public Health Service Act, and other legal or policy requirements. 
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o CDC may, in the interests of research participants, apply stricter standards than 
legally required. 
• Carrying out human research that is exempted or waived in accordance with 45 CFR 
46.101(b) or (i): 
CDC must apply principles of ethical research, including provisions for ensuring scientific 
quality and integrity, appropriate benefit-harm balance, just research, and, where 
practicable, for obtaining free and informed consent. 
• Assisting or collaborating on human research or clinical investigations when CDC has 
no institutional responsibilities under human research regulations (such as providing 
nonfinancial technical assistance to a co-investigator or a ministry of health): 
o CDC must ensure that assisted or collaborative partners apply principles of ethical 
research and comply with local regulatory requirements. 
o CDC may extend coverage of CDC’s FWA or CDC IRBs to nonsupported partners 
who are conducting human research or clinical investigations to facilitate 
application of ethical principles and regulatory norms. 
• Setting priorities and allocating resources for research: 
CDC must set priorities according to the principles of beneficence and justice, to the 
extent permitted by appropriations and allocation processes. 
• Applying or disseminating knowledge derived from human research (such as 
coauthoring a manuscript or writing public health guidelines): 
o CDC must ensure that manuscripts, guidelines, released data, and other 
information products are based on information that was obtained in accordance 
with appropriate ethical principles and regulatory requirements. 
o CDC must ensure that approved research yields information products that 
disseminate the knowledge gained. Failing to do so undermines the original 
justification and approval of such research. 
5. RESPONSIBILITIES 
All persons covered by this policy are responsible for being familiar with human research 
regulations, this policy, and related policies and practices as they relate to their official 
duties. In addition to role-based responsibilities listed below, individuals might have 
additional responsibilities that are not listed.  This process begins with investigators and 
proceeds through National Centers and, where applicable, HRPO or a CDC IRB as 
described in the appendix.  
A. Investigators  
As defined below in the definition section, this includes all CDC employees and agents, as 
well as others acting under CDC’s FWA through an individual investigator agreement. 
1. Prior to serving as investigators, certify HRPO-approved education in research ethics 
and human research regulations and obtain certification of competency. 
2. Maintain competency in research ethics and human research regulations and certify at 
least once every 3 years. 
3. Submit proposed activities for human research review under National Center (NC) 
procedures, including research/nonresearch determinations and exempt/nonexempt 
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human research. Ensure that the design of proposed activities conforms to acceptable 
scientific, ethical, and legal requirements. Determine that the resources necessary to 
protect participants are present before conducting the research study. Declare 
competing interests. 
4. For nonexempt human research or clinical investigations conducted by CDC, obtain 
IRB approval prior to CDC’s conducting the activity. This approval must generally be 
obtained before involving human participants, unless CDC undertakes collaboration 
on a project that has previously been approved by one or more other IRBs. 
a. Adhere to all terms of IRB approval and implement the protocol as approved. 
Do not deviate from approved protocol except (a) when prior approval is 
obtained from the IRB of record or (b) when necessary to eliminate apparent 
immediate hazards to participants. Follow the protocol’s monitoring plan, if any. 
b. Promptly inform the IRB of unanticipated problems involving risks to 
participants or others, deviations to eliminate apparent immediate hazards to 
participants, serious or continuing noncompliance, and substantive complaints 
from participants. 
c. Ensure that free and informed consent is obtained and documented from each 
participant or his/her legally authorized representative, unless the IRB of 
record has approved an alternative approach. 
d. Obtain continuing IRB approval before it lapses. 
e. Cease conducting a research activity when IRB approval lapses. 
f. Close research study with HRPO when CDC is no longer conducting the 
research activity. 
5. Maintain study-related records according to legal and policy requirements. 
6. Serve as primary contact for HRPO, or designate alternative contact. 
7. Serve as primary contact for communication about human research protections with 
research partners. 
8. Serve as primary contact with participants, when applicable. 
9. Ensure appropriate protections, such as for privacy and confidentiality, when research 
is not covered by human research regulations (e.g., because it is exempt or because 
CDC is not engaged). 
10. Ensure that collaborative partners and recipients of technical assistance apply 
appropriate ethical and regulatory norms. 
11. Demonstrate that research-related information products that are submitted for 
clearance have been derived from research that complies with human research ethics 
and regulations. 
12. Comply with required remediation and other sanctions. 
B. Supervisors 
This includes employees with responsibility for administrative supervision, such as team 
leaders, branch chiefs, division directors, and National Center directors. 
1. Certify HRPO-approved education in research ethics and human research regulations 
and obtain certification of competency. 
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2. Maintain competency in research ethics and human research regulations and certify at 
least once every 3 years. 
3. Ensure that each human research activity has adequate resources, such as 
enrollment capacity, time for completion, and qualified staff. 
4. Authorize commitment of financial and nonfinancial support for human research. 
5. Ensure that research staff have adequate provisions for conducting human research, 
including education, experience, and supervision in appropriate scientific, ethical, 
legal, and policy-related practices. Facilitate preparation, review, and maintenance of 
human research activities. 
6. Promote and permit service on CDC IRBs on balance with other needs in supervised 
program. 
7. Enforce remediation and other sanctions of CDC research staff when applicable, such 
as revoking authorship or other credit, disallowing service as an investigator, and 
initiating personnel actions. 
8. Authorize release of nonfinancial support for human research, including identifiable 
private information, supplies, products, drug, other tangible support. 
9. Ensure appropriate protections, such as for privacy and confidentiality, when research 
is not covered by human research regulations (e.g., because it is exempt or because 
CDC is not engaged). 
10. Ensure that collaborative partners and recipients of technical assistance apply 
appropriate ethical and regulatory norms. 
11. Demonstrate that research-related information products that are submitted for 
clearance have been derived from research that complies with human research ethics 
and regulations. 
C. Associate Directors for Science 
This includes Associate Directors for Science or equivalent scientific oversight roles at 
branch, division, and National Center levels. 
1. Certify HRPO-approved education in research ethics and human research regulations 
and obtain certification of competency. 
2. Maintain competency in research ethics and human research regulations and certify at 
least once every 3 years. 
3. Provide guidance to and mentor investigators and supervisors on scientific, ethical, 
legal, and policy-related practices for human research. 
4. Perform timely regulatory, ethical, and scientific reviews when routing proposals, 
including research categorization, human participant involvement, agency 
engagement, regulatory exemptions, routing to CDC or non-CDC IRB, and other 
related reviews. Ensure that the research uses procedures consistent with sound 
research design sufficient to yield the expected knowledge and that each protocol has 
sufficient resources. Determine that the resources necessary to protect participants 
are present before permitting the research study. Assess investigators’ competing 
interests.  
5. As a condition for clearing information products, ensure appropriate compliance with 
scientific, ethical, legal, and policy-related requirements. Require that research-related 
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information products that are submitted for clearance have been derived from 
research that complies with human research ethics and regulations. 
6. Facilitate enforcement of remediation and other sanctions of CDC research staff, 
when applicable. 
7. Authorize release of nonfinancial support for human research, including identifiable 
private information, supplies, products, drug, other tangible support. 
8. Ensure appropriate protections, such as for privacy and confidentiality, when research 
is not covered by human research regulations (e.g., because it is exempt or because 
CDC is not engaged). 
9. Ensure that collaborative partners and recipients of technical assistance apply 
appropriate ethical and regulatory norms. 
D. Human Research Protection Coordinators 
This includes Human Research Protection Coordinators or equivalent human research 
analyst roles at branch, division, and National Center levels. 
1. Certify HRPO-approved education in research ethics and human research regulations 
and obtain certification of competency. 
2. Maintain competency in research ethics and human research regulations and certify at 
least once every 3 years. 
3. Provide guidance to investigators and supervisors on scientific, ethical, legal, and 
policy-related practices for human research. 
4. Perform timely regulatory and ethical reviews when routing proposals, including 
research categorization, human participant involvement, agency engagement, 
regulatory exemptions, routing to CDC or non-CDC IRB, and other related reviews.  
5. Coordinate and facilitate formal communication with HRPO and IRBs of record. 
6. Ensure appropriate protections, such as for privacy and confidentiality, when research 
is not covered by human research regulations (e.g., because it is exempt or because 
CDC is not engaged). 
7. Ensure that collaborative partners and recipients of technical assistance apply 
appropriate ethical and regulatory norms. 
8. Demonstrate that research-related information products that are submitted for 
clearance have been derived from research that complies with human research ethics 
and regulations. 
E. Other program staff 
This includes other staff at the team, branch, division, or National Center level with 
responsibilities in CDC’s human research protection program, such as contracting officers. 
1. Ensure that funding proposals comply with human research regulations. When 
necessary, ensure that awardees hold a valid FWA and certify IRB approval. 
2. Authorize disbursement of funds for human research activities (whether through 
assistance or acquisition mechanisms) only after human research protection 
requirements are met and documented. 
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F. Institutional official 
The designated Signatory Official on CDC’s FWA is authorized to do the following: 
1. Exercise the responsibility of the CDC Director, under 45 CFR 46.103(c), to provide 
formal, legally binding assurance regarding policy.  
2. Exercise the authority and responsibility for assuring CDC-wide compliance with all 
applicable laws, regulations, policies, and standards regarding the protecting the rights 
and welfare of human participants of research conducted or supported by CDC.  
3. Serve as the institutional official for purposes of compliance with 45 CFR part 46 and 
21 CFR parts 50 and 56. 
4. Set the tone for the agency by promoting an institutional culture of respect and 
conscience, so that the ethical conduct of human research is supported at the highest 
levels of the organization. 
5. Ensure that the human research protection program functions effectively and that 
CDC provides the resources and support necessary to comply with all requirements 
applicable to human research. Monitor and measure the effectiveness of CDC’s 
human research protection program, plan improvements based on those measures, 
implement planned improvements, and monitor and measure the effectiveness of 
those improvements. 
6. Designate IRBs that will review research covered by CDC's FWA as well as clinical 
investigations covered by FDA regulations. 
7. Provide sufficient resources, space, and staff to support the IRBs’ review and record-
keeping duties.  
8. Respect, support, and defend the autonomy of CDC IRBs and other IRBs of record to 
act within their purview. 
9. Ensure effective institutionwide communication and guidance on human research 
protections. 
10. Ensure that investigators fulfill their scientific, ethical, legal, and policy-related 
responsibilities. 
11. Provide investigators with ways to obtain answers to questions, express concerns, 
and convey suggestions regarding the HRPP to someone outside of the IRB. 
12. Encourage all staff involved in the conduct or oversight of human research to 
participate in ongoing education activities. 
13. Ensure appropriate protections, such as for privacy and confidentiality, when research 
is not covered by human research regulations (e.g., because it is exempt or because 
CDC is not engaged). 
14. Ensure that collaborative partners and recipients of technical assistance apply 
appropriate ethical and regulatory norms. 
15. Require that research-related information products that are submitted for clearance 
have been derived from research that complies with human research ethics and 
regulations. 
Neither the institutional official nor any other CDC official may approve research that has 
been disapproved or not yet approved by the IRB of record or whose IRB approval has 
lapsed or been suspended or terminated. 
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G. Human Research Protection Office (and successor offices) 
The chief of HRPO shall be designated on CDC’s FWA as the Human Protections 
Administrator. The HRPO chief exercises operational responsibility for CDC’s human 
research protection program and is responsible for maintaining comprehensive knowledge 
of all aspects of CDC’s human research protection program, for being familiar with CDC’s 
commitments under the FWA, and for playing a key role in ensuring that CDC fulfills its 
responsibilities under the FWA. Through this policy, the institutional official delegates the 
following responsibilities to the chief of HRPO, who may redelegate these responsibilities 
to HRPO staff through written operating procedures. 
1. Serve as a knowledgeable point of contact for OHRP, FDA, and other federal 
agencies regarding research ethics and human research regulations. 
2. Maintain CDC’s FWA and IRB registrations, including timely revisions to CDC IRB 
rosters and the list of IRBs on whom CDC may rely. 
3. Recruit and appoint members to CDC IRBs, in consultation with the respective board 
chairs. Appoint the IRB chair and vice-chairs. Manage support for unaffiliated IRB 
members. Suspend or terminate the membership of any individual who does not fulfill 
membership responsibilities. 
4. Perform periodic evaluation of the performance of administrative staff and IRB 
members. 
5. Ensure that administrative staff, IRB members, and investigators are knowledgeable 
to conduct research in accordance with ethical standards and all applicable 
regulations. Develop and implement an educational plan for administrative staff, IRB 
members, and investigators. 
6. Work with the HRPO chief’s supervisors to ensure that adequate personnel, space, 
and other resources are allocated to the HRPP.  
7. Review and determine which activities involving CDC investigators are exempt under 
45 CFR 46.101(b). 
8. Review and sign IRB authorization agreements, individual investigator agreements, 
and similar documents between CDC’s HRPP and other parties, as appropriate. 
9. Serve as the contact for correspondence addressing human research with OHRP, 
FDA, and other agencies as applicable, including incident reports, certifications under 
45 CFR part 46 subpart C, and the PHS Policy on Informing Those Tested About HIV 
Serostatus. 
10. Develop, review, and approve standard operating procedures (SOPs) for the HRPP, 
including HRPO’s administrative functions and IRB functions.  
11. Oversee daily operations of the HRPP and IRBs in accordance with the SOPs. 
12. Assess and manage institutional competing interests. Manage IRB members’ 
competing interests. 
H. NCHS and NIOSH  
NCHS and NIOSH each support a CDC IRB. Each of these IRBs operates as part of CDC 
as an IRB organization under the terms of CDC’s FWA.  
1. To support management of these IRBs that is efficient and complies with CDC’s legal 
and ethical obligations, the CDC institutional official and the chief of HRPO may 
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delegate specific authorities and responsibilities to the Directors or Associate Directors 
for Science of NCHS and NIOSH through standard operating procedures.  
2. These authorities and responsibilities may be redelegated, for example, to a human 
research protection coordinator or an IRB administrator.  
3. To the extent feasible, these authorities and responsibilities shall be coordinated with 
HRPO’s standard operating procedures. 
I. Procurement and Grants Office 
The CDC Procurement and Grants Office shall ensure that no funds are disbursed to an 
awardee in support of nonexempt human research, whether through an assistance 
mechanism or an acquisition mechanism, unless each awardee that will become engaged 
in nonexempt human research holds a valid federalwide assurance with OHRP and 
certifies that the research has been reviewed and approved by an IRB provided for in the 
approved assurance and will be subject to continuing review by the IRB. 
J. CDC IRBs 
1. Members must fulfill membership responsibilities as stipulated in HRPO SOPs, 
including meeting attendance and declarations of competing interests. 
2. Foremost, members must protect the rights and welfare of research participants in all 
research under their purview, whether conducted by CDC or by an outside institution 
relying on a CDC IRB. Board actions must comply with ethical norms and legal and 
policy-related requirements, including federal human research regulations, guidance, 
and Departmental2 and CDC 3
3. Chairs and vice-chairs, with assistance from HRPO staff, are responsible for leading 
and setting the tone for each IRB, running convened meetings, striving for an 
appropriate degree of consistency across actions within and between CDC IRBs, 
overseeing the development and actions of members, and serving on the CDC IRB 
executive committee. 
 policy. This policy expressly releases CDC IRB 
members from any perceived responsibility to protect CDC, its programs, or its 
investigators, except where such protections are in the interests of research 
participants or compliance with ethical norms and legal and policy-related 
requirements. 
4. Chairs have full discretion over the appointment and retention of members on their 
boards, in compliance with legal and policy-related requirements for board 
composition. 
5. As an IRB organization, CDC promotes open communication between CDC IRB 
members and CDC investigators. Nonetheless, chairs have full discretion over the 
management of board meetings, in compliance with legal and policy-related 
requirements for board meetings.  
6. The CDC IRB executive committee, comprised of CDC IRB chairs and vice-chairs and 
the HRPO chief, is responsible for ratifying standard procedures related to the 
management of board functions. Furthermore, the executive committee is a resource 
for boards seeking guidance on complex or difficult actions, such as termination of 
                                               
2 Departmental policies include the PHS Policy on Informing Those Tested About HIV Serostatus. 
3 CDC policies include Inclusion of Women and Racial and Ethnic Minorities in Research and 
Inclusion of Persons under the Age of 21 in Research. 
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approval. Because each board is autonomous, this resource is used at the discretion 
of the board itself. 
6. ACRONYMS AND ABBREVIATIONS 
ADS – Associate Director for Science 
FDA – Food and Drug Administration 
FWA – federalwide assurance 
HHS – Department of Health and Human Services 
HRPC – human research protection coordinator 
HRPO – Human Research Protection Office 
HRPP – Human Research Protection Program 
IRB – institutional review board 
NC – national center 
NCHS – National Center for Health Statistics 
NIOSH – National Institute for Occupational Safety and Health 
OHRP – Office for Human Research Protections 
SOP – standard operating procedure 
7. DEFINITIONS 
Agent – A nonemployee of CDC who conducts research under CDC’s FWA. This 
generally includes all persons cleared for access to CDC networks and who use CDC 
networks or physical facilities for human research activities. 
Clinical investigation – any experiment that involves a test article and one or more human 
participants and that either is subject to requirements for prior submission to the FDA 
or the results of which are intended to be submitted later to, or held for inspection by, 
the FDA as part of an application for a research or marketing permit. The term does 
not include certain nonclinical laboratory studies. 
Conduct a clinical investigation – direct the administration to, dispensing of, or use 
involving a test article with a participant. 
Conduct research – To be engaged in human research by obtaining, using, studying, or 
analyzing data about living individuals through intervention or interaction with them for 
research purposes or by obtaining using, studying, or analyzing individually identifiable 
private information about living individuals for research purposes. 
Engagement – An institution becomes engaged in human subjects research when its 
employees or agents (i) obtain data about living individuals through intervention or 
interaction with them for research purposes; or (ii) obtain individually identifiable 
private information about living individuals for research purposes. Furthermore, an 
institution is automatically considered to be engaged in human subjects research 
whenever it receives a direct HHS award to support such research, even where all 
activities involving human subjects are carried out by a subcontractor or collaborator.  
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Exempt human subjects research - Categories of research to which the Federal 
regulations for human research protections do not apply. Research involving prisoners 
and some research involving children are not exempt. See also 45 CFR 46.101(b), (i). 
Federalwide assurance – A written document submitted by an institution that is engaged 
in nonexempt human research conducted or supported by HHS. Through the 
assurance, an institution commits to HHS that it will comply with the requirements set 
forth in the regulations for the protection of human participants at 45 CFR part 46. 
Human research protection coordinator – Individual designated by each NC and some 
divisions to coordinate human research protections within the NC or division, by 
serving as a resource to investigators and other program staff and as a point of 
contact with other portions of CDC’s human research protection program. 
Human Research Protection Office – The organizational unit within CDC that is charged 
with facilitating the work of CDC IRBs and providing assistance and training for CDC 
staff engaged in research involving human participants, including clinical 
investigations. 
Human subject or participant – A living person about whom an investigator conducting 
research obtains (1) data through intervention or interaction with the individual, or (2) 
identifiable private information (e.g., medical records, employment records, or school 
records). In a clinical investigation, a human who participates in an investigation, as a 
recipient of a test article, as an individual on whom or on whose specimen an 
investigational device is used, or as a control. 
Institutional official – The individual who is legally authorized to act for the institution and, 
on behalf of the institution, obligates the institution to the FWA and other ethical 
commitments regarding human research. 
Institutional review board – A formally appointed ethics review committee established to 
ensure that research involving human participants conforms to ethical principles and 
federal regulations. 
Investigator – Any individual who is involved in conducting human research activities. 
IRB of record – The designated IRB that oversees a specific research activity or clinical 
investigation conducted by an investigator or institution. 
Research – A systematic investigation, including research development, testing and 
evaluation, designed to develop or contribute to generalizable knowledge. 
Sponsor – A person (e.g., an individual, corporation, or agency) who initiates a clinical 
investigation. 
Support – Provision of funding, identifiable private information, or supplies, products, drug, 
other tangible support. Does not include mere provision of Federal staff time and 
assistance absent other forms of financial or material support. 
Test article – Any drug, biological product, or medical device for human use. 
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[http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.htm] 
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Activities that meet the regulatory definitions of human research or clinical investigation 
may be exempt from some or all regulatory requirements, or CDC’s role may be such that 
CDC has no regulatory responsibilities (because, for example, CDC is neither conducting 
nor supporting the activity). Therefore, CDC’s human research protection program 
implements a multi-tiered process for carefully categorizing activities according to these 
definitions and their respective regulatory and ethical requirements. This process begins 
with investigators and proceeds through National Centers and, where applicable, HRPO 
or a CDC IRB. 
(1) Investigators 
HHS-defined research involving human participants 
For each activity that involves obtaining, using, studying, or analyzing information from or 
about individual humans, a CDC investigator provisionally determines the following in 
consultation with the human research protection coordinator: 
a. Whether the activity constitutes research, as defined at 45 CFR 46.102(d) and 
interpreted in CDC Policy CDC-SA-2010-02, Distinguishing Public Health Research and 
Public Health Nonresearch; 
b. If the activity constitutes research, whether it involves human participants (§102(f)); 
c. If the activity is research involving human participants, whether CDC is conducting 
(i.e., is engaged in) or supporting the human research activity; 
d. If CDC is conducting the human research activity, whether it is exempt per 45 CFR 
46.101(b); 
e. If CDC is conducting a nonexempt human research activity; 
f. Whether to seek approval by a CDC IRB or an IRB on which CDC relies, and 
g. Whether nonsupported research partners are also engaged in nonexempt human 
research; 
h. If CDC is supporting the human research activity, whether supported research 
partners are engaged in human research, and if so whether the human research is 
exempt or nonexempt. 
i. If an activity constitutes human research but CDC is neither conducting nor supporting 
the activity, the investigator determines that CDC’s association with and participation in 
the research activity is consistent with ethical norms. 
j. If a research activity is undertaken without the intention of involving human 
participants, but it is later proposed to involve human participants in the research, the 
investigator reiterates this decision process and pursues appropriate approval prior to the 
involvement of human participants. 
k. If an activity description lacks definite plans for involvement of human participants, no 
human participants may be involved in the activity until the investigator reiterates this 
decision process and pursues appropriate approval. 
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l. The investigator initiates review sufficient to document decisions about whether an 
activity constitutes research or not, involves human participants or not, is conducted or not 
conducted by CDC, is exempt or not, is supported or not supported by CDC, and involves 
research partners for which additional documentation may be required. 
m. The investigator must receive appropriate permission or approval before undertaking 
any research activity that involves obtaining or using information from or about individual 
humans. 
FDA-defined clinical investigations 
For each activity that involves a drug, biologic, or device (including in vitro diagnostics), a 
CDC investigator determines the following: 
a. Whether the activity constitutes a clinical investigation involving one or more human 
participants, including 
b. Whether the investigation is an experiment in which a drug or biologic is administered 
or dispensed to a human participant, except for the use of a marketed drug in the 
course of medical practice, and 
c. Whether the investigation is intended to determine the safety or effectiveness of a 
device; 
d. If the activity constitutes a clinical investigation,  
• Whether CDC initiates the investigation, and 
• Whether the CDC investigator directs or dispenses the test article or uses it with a 
human participant (including a human specimen). 
e. If an activity constitutes a clinical investigation but CDC is neither conducting nor 
sponsoring the investigation, the investigator determines that CDC’s association with 
and participation in the investigation is consistent with ethical norms. 
• The investigator initiates review sufficient to document decisions about whether an 
activity constitutes a clinical investigation or not, involves CDC as a sponsor or 
investigator, and involves research partners for which additional documentation 
may be required. 
• The investigator must receive appropriate approval before undertaking any clinical 
investigation. 
Activities that meet both the HHS definition and the FDA definition 
If an activity meets both definitions, the investigator is responsible for obtaining 
appropriate approval under both HHS and FDA regulations before undertaking the activity. 
This generally occurs in a single review process which entails additional regulatory burden 
only where the regulations entail different requirements, in which case the stricter 
requirements prevail. 
Activities that meet neither the HHS definition nor the FDA definition 
a. The investigator initiates review sufficient to document decisions that an activity meets 
neither definition if the activity involves obtaining or using information on or about 
individuals or involves use of drugs or devices. 
b. The investigator must obtain documented decisions from the National Center before 
undertaking such activities. 
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(2) Division-level oversight officials 
a. For each proposed activity, the division ADS or designee documents the following: 
• whether the activity constitutes research, as defined at 45 CFR 46.102(d) and 
interpreted in CDC Policy CDC-SA-2010-02, Distinguishing Public Health 
Research and Public Health Nonresearch; 
• if the activity constitutes research, whether it involves human participants (§102(f)); 
• for nonexempt human research, whether CDC is conducting (i.e., is engaged in) 
the human research activity; and, 
• whether the activity constitutes a clinical investigation involving one or more 
human participants and one or more CDC investigators. 
b. The division ADS or designee determines whether the proposed research or clinical 
investigation satisfies appropriate legal, ethical, and scientific norms. The division ADS 
or designee ensures that the research uses procedures consistent with sound 
research design sufficient to yield the expected knowledge and that each protocol has 
sufficient resources and determines that the resources necessary to protect 
participants are present before permitting the research study. 
c. The division ADS or designee routes to the NC ADS or designee requests for 
exemption or for IRB review of nonexempt, CDC-conducted human research or 
clinical investigations. 
(3) NC-level oversight officials 
a. For each proposed activity, the NC ADS, NC HRPC, or designee documents the 
following: 
• whether the activity constitutes research, as defined at 45 CFR 46.102(d) and 
interpreted in CDC Policy CDC-SA-2010-02, Distinguishing Public Health 
Research and Public Health Nonresearch; 
• if the activity constitutes research, whether it involves human participants (§102(f)); 
• whether CDC is conducting (i.e., is engaged in) the human research activity; and, 
• if CDC is conducting the human research activity, whether it is exempt per 45 CFR 
46.101(b); 
• whether the activity constitutes a clinical investigation involving one or more 
human participants and one or more CDC investigators. 
b. The NC ADS or designee determines whether the proposed research or clinical 
investigation satisfies appropriate legal, ethical, and scientific norms. The NC ADS or 
designee ensures that the research uses procedures consistent with sound research 
design sufficient to yield the expected knowledge and that each protocol has sufficient 
resources and determines that the resources necessary to protect participants are 
present before permitting the research study. 
c. The NC ADS or designee routes to HRPO requests for exemption or for IRB review of 




The HRPO-specific procedures described in this section may also be carried out under 
authorities that has be delegated to the ADSs of National Center for Health Statistics 
(NCHS) and National Institute for Occupational Safety and Health (NIOSH), as applicable. 
a. HRPO reviews nonresearch activities only in the following circumstances: 
• The activity is a clinical investigation that requires IRB approval 
• The activity entails a request to test HIV serostatus that is linked to participants by 
an identifier and for which a participant might not receive the test result; or 
• A scientific program consults with HRPO about interpreting the definition of 
research 
b. When HRPO receives a request to review a human research activity for which no 
specific human research regulations apply to CDC, HRPO may decline to manage 
further review of the activity; HRPO must notify the requesting program accordingly. 
c. When an investigator requests a finding that a human research activity is exempt per 
45 CFR 46.101(b), the chief of HRPO, or designee, renders and documents that 
finding on behalf of CDC. If the activity is deemed nonexempt, it is referred back to the 
program for rerouting. 
d. When an investigator requests review by a CDC IRB for a nonexempt human research 
activity conducted by CDC (i.e., in which CDC is engaged), or for a clinical 
investigation conducted by CDC, HRPO manages the review. When an activity falls 
under more than one set of requirements, HRPO ensures that the reviewing IRB 
applies the stricter requirements. 
e. When an investigator requests review by a non-CDC IRB for a nonexempt human 
research activity conducted by CDC (i.e., in which CDC is engaged), or for a clinical 
investigation conducted by CDC, HRPO manages the process of arranging an IRB 
authorization agreement and listing the reviewing IRB on CDC’s FWA. 
f. When an outside institution requests review by a CDC IRB for a nonexempt human 
research activity or clinical investigation conducted by that institution, HRPO manages 
the IRB authorization agreement and IRB review. When an activity falls under more 
than one set of requirements, HRPO ensures that the reviewing IRB applies the 
stricter requirements. 
 
